Marina Sherman, NP
Family · Brooklyn, NYNPI 1598064743
Payments from drug & device makers
Across 383 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Boehringer Ingelheim$1K
- Novo Nordisk$1K
- Novartis$795
- Lilly USA, LLC$652
- Kowa Pharmaceuticals America, Inc.$441
- plus $2K from 14 others
What the payments were for
- Food & beverage$8,047100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 95 | $2,016 |
| Boehringer Ingelheim | 56 | $1,213 |
| Novo Nordisk | 54 | $1,063 |
| Novartis | 29 | $795 |
| Lilly USA, LLC | 32 | $652 |
| Kowa Pharmaceuticals America, Inc. | 27 | $441 |
| Sanofi-aventis U.S. LLC | 20 | $424 |
| Amarin Pharma, Inc. | 25 | $415 |
| AstraZeneca | 10 | $258 |
| Amneal Pharmaceuticals LLC | 9 | $186 |
| Radius Health, Inc. | 7 | $185 |
| Alnylam Pharmaceuticals Inc. | 3 | $93 |
| Recordati_rare_diseases_inc. | 3 | $64 |
| Almatica Pharma LLC | 3 | $64 |
| Merck | 4 | $58 |
| Bayer | 2 | $49 |
| Medicure Pharma Inc. | 1 | $32 |
| Alvogen Inc | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| GSK | 1 | $13 |
How this compares
$8,068 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 447 | $491,091 |
| TrulicityDulaglutide | 360 | $398,893 |
| MounjaroTirzepatide | 274 | $347,225 |
| ProliaDenosumab | 188 | $309,006 |
| JardianceEmpagliflozin | 394 | $288,484 |
| VascepaIcosapent Ethyl | 519 | $185,917 |
| TradjentaLinagliptin | 297 | $172,463 |
| FarxigaDapagliflozin Propanediol | 162 | $103,889 |
| Metformin Er GastricMetformin Hcl | 42 | $103,873 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 133 | $100,140 |
| Tresiba Flextouch U-200Insulin Degludec | 141 | $99,029 |
| Repatha SureclickEvolocumab | 163 | $98,380 |
| JanumetSitagliptin Phos/Metformin Hcl | 148 | $94,176 |
| Pitavastatin Calcium | 234 | $89,047 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 146 | $87,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $652 | $746,117634 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Trijardy Xr, Jentadueto Xr | $1,213 | $724,0111,119 claims |
| Novo NordiskOzempic, Rybelsus | $1,063 | $562,049497 claims |
| AmgenProlia | $2,016 | $309,006188 claims |
| MerckJanumet, Janumet Xr, Januvia | $58 | $196,707319 claims |
| AstraZenecaFarxiga | $258 | $103,889162 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $441 | $30,11974 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $424 | $10,23812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.